[Federal Register Volume 60, Number 246 (Friday, December 22, 1995)]
[Notices]
[Pages 66553-66554]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-31153]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 95N-0403]
Drug Export; SURGISCREEN 0.8 Percent, Reagent Red Blood
Cells
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that
Ortho Diagnostic Systems, Inc., has filed an application requesting
approval for the export of the human biological product
SURGISCREEN 0.8 percent, Reagent Red Blood Cells to
Australia, Austria, Belgium, Canada, Denmark, The Federal Republic of
Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg,
The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden,
Switzerland, and The United Kingdom.
ADDRESSES: Relevant information on this application may be directed to
the Dockets Management Branch (HFA-305), Food and Drug Administration,
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, and to the contact
person identified below. Any future inquiries concerning the export of
human biological products under the Drug Export Amendments Act of 1986
should also be directed to the contact person.
FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics
Evaluation and Research (HFM-610), Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852-1448, 301-594-2006.
SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)
provide that FDA may approve applications for the export of human
biological products that are not currently approved in the United
States. Section 802(b)(3)(B) of the act sets forth the requirements
that must be met in an application for approval. Section 802(b)(3)(C)
of the act requires that the agency review the application within 30
days of its filing to determine whether the requirements of section
802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act
requires that the agency publish a notice in the Federal Register
within 10 days of the filing of an application for export to facilitate
public participation in its
[[Page 66554]]
review of the application. To meet this requirement, the agency is
providing notice that Ortho Diagnostic Systems, Inc., 1001 U.S. Highway
202, Raritan, NJ 08869-0606, has filed an application requesting
approval for the export of the human biological product
SURGISCREEN 0.8 percent, Reagent Red Blood Cells to
Australia, Austria, Belgium, Canada, Denmark, The Federal Republic of
Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg,
The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden,
Switzerland, and The United Kingdom. The SURGISCREEN 0.8
percent, Reagent Red Blood Cells, is an in vitro diagnostic test kit
for the detection of unexpected blood group antibodies in test methods
requiring a 0.8 percent red cell suspension in a low ionic strength
diluent. The application was received and filed in the Center for
Biologics Evaluation and Research on November 24, 1995, which shall be
considered the filing date for purposes of the act.
Interested persons may submit relevant information on the
application to the Dockets Management Branch (address above) in two
copies (except that individuals may submit single copies) and
identified with the docket number found in brackets in the heading of
this document. These submissions may be seen in the Dockets Management
Branch between 9 a.m. and 4 p.m., Monday through Friday.
The agency encourages any person who submits relevant information
on the application to do so by (insert date 10 days after date of
publication in the Federal Register), and to provide an additional copy
of the submission directly to the contact person identified above, to
facilitate consideration of the information during the 30-day review
period.
This notice is issued under the Federal Food, Drug, and Cosmetic
Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the
Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the
Center for Biologics Evaluation and Research (21 CFR 5.44).
Dated: December 4, 1995.
James C. Simmons,
Director, Office of Compliance, Center for Biologics Evaluation and
Research.
[FR Doc. 95-31153 Filed 12-21-95; 8:45 am]
BILLING CODE 4160-01-F
